Form 13D/A CVRx For: 2 October By Investing.com
This article from Investing.com announces the filing of Form 13D/A for CVRx on October 2nd. It is a brief, news-focused piece, typical of a financial news wire service. The content is essentially a headline repeated within the body.
Share sales take a holder below 5% ownership of CVRx (CVRX).
Jorey Chernett has reduced his stake in CVRx (CVRX) to approximately 0.62% of the common stock as of October 2, 2026, after selling shares. This action, described as an "exit filing," means he no longer beneficially owns more than 5% of the company's outstanding shares. Chernett's decision to sell shares stemmed from a difference of opinion with CVRx management regarding the company's strategic direction.
Investigation launched into CVRx over DOJ probe and sales issues causing stock plunge
Hagens Berman has initiated an investigation into CVRx Inc. following a U.S. Department of Justice Civil Investigative Demand concerning potential false claims and kickbacks related to its Barostim heart failure device. This comes after CVRx reported significant operational problems, including reduced revenue guidance, sales force disruptions, and a decline in Medicare Advantage approvals, leading to a 59% stock plunge and the termination of its Chief Revenue Officer. The investigation will examine whether CVRx misled investors and if the DOJ probe is connected to the CRO's firing.
$CVRX stock is down 33% today. Here's what we see in our data.
CVRX stock experienced a 33% drop today, with approximately $7.46 million in trading volume. Insider trading data shows the Chief Operating Officer, Brent Binkowski, made both purchases and sales of CVRX stock in the last six months. Institutional activity indicates a mixed sentiment, with 39 investors increasing and 43 decreasing their positions in Q2 2026, including significant moves by BALYASNY ASSET MANAGEMENT L.P. and ROYAL BANK OF CANADA.
New registry analyses of a heart failure device are scheduled for a late-breaking session.
CVRx (NASDAQ: CVRX) announced its Barostim device will be featured in eight events, including late-breaking clinical data and podium sessions, at the HFSA Annual Scientific Meeting 2026. New analyses from the REBALANCE Registry, evaluating Barostim’s safety and benefits in commercial use, will be presented by Dr. Dmitry Yaranov. Additionally, Dr. Javed Butler will present real-world evidence on Baroreflex Activation Therapy in heart failure with mid-range ejection fraction (HFmrEF), focusing on reduced hospitalization burden.
CVRx Announces Late-Breaking Data and New Clinical Evidence
CVRx, Inc. announced the schedule of scientific presentations for its Barostim device at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. The meeting will feature late-breaking clinical data from the REBALANCE Registry and new real-world evidence on Barostim for heart failure with preserved ejection fraction (HFmrEF), alongside several other sessions and two sponsored symposia. This highlights Barostim's role in the heart failure care continuum and provides new insights across patient populations and clinical outcomes.
CVRX Oct 2026 5.000 put (CVRX261016P00005000) Stock Price, News, Quote & History
This page provides financial information for the CVRX Oct 2026 5.000 put option, identified by the ticker CVRX261016P00005000. It displays the current price, historical data, and key metrics such as previous close, open, bid, ask, strike price, and expiration date. The page also includes chart data and volume information for the option.
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
Hagens Berman, a national shareholder rights litigation firm, has launched an investigation into CVRx Inc. (NASDAQ: CVRX) for potential federal securities law violations. This follows a 59% stock drop after disclosures of a DOJ Civil Investigative Demand, significant revenue guidance cuts, sales force issues, and the sudden termination of the company's Chief Revenue Officer. The firm is encouraging investors with substantial losses to contact them to evaluate their legal options.
CVRx Inc. (CVRX) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live stock quotes and charts for CVRx Inc. (CVRX) on NASDAQ, showing a current price of $2.70 with a 6.72% increase. It notes that there is no current information on analyst ratings or earnings for the company. The page also offers various trading resources and promotional content for stock trading tools.
CVRx names John Landry as CFO
CVRx has appointed John Landry as its new CFO, effective October 12, as the company faces pressure to improve commercial performance of its Barostim heart failure device. Landry, who previously served as CFO for Nyxoah and Vapotherm, joins CVRx after an activist investor called for the company's sale due to repeated revenue forecast cuts and perceived underperformance. The company's CEO, Kevin Hykes, expressed confidence in Landry's experience in high-growth medical device companies to navigate this critical period.
Lake Street Downgrades CVRx Inc(CVRX.US) to Hold Rating, Cuts Target Price to $3.5
Lake Street has downgraded CVRx Inc (CVRX.US) from a Buy rating to a Hold rating. The firm also significantly reduced its price target for CVRx from $18 to $3.5. This comes after CVRx Inc. announced an underwritten public offering of 11,000,000 shares of its common stock.
CVRx, Inc. (CVRX) stock price, news, quote and history
This page provides a comprehensive overview of CVRx, Inc. (CVRX) stock, including its current price, historical data, financial statistics, and analyst ratings. CVRx, Inc. is a medical device company specializing in neuromodulation solutions for cardiovascular diseases, with its primary product being Barostim. The company's financial performance shows a negative profit margin and EPS, with analysts providing an average target price of $4.58.
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Hold Rating
Craig-Hallum has reiterated a Hold rating for CVRx Inc (CVRX.US). This suggests the firm believes the stock will perform in line with the broader market and advises investors to maintain their current positions.
CVRx taps new CFO from Nyxoah
CVRx has appointed John Landry as its new Chief Financial Officer, effective October 12, following the resignation of Jared Oasheim. Landry joins CVRx from Nyxoah, bringing extensive experience in financing high-growth medical device companies. His appointment comes amidst other executive departures, a federal investigation into marketing practices, and activist investor pressure for the company to consider a sale.
CVRx appoints John Landry as chief financial officer By Investing.com
CVRx Inc. has announced the appointment of John Landry as its new Chief Financial Officer, succeeding Jared Oasheim. Landry, currently CFO of Nyxoah SA, will join CVRx on October 12, 2026, and officially take over after the company files its Q3 2026 Form 10-Q. CVRx develops neuromodulation solutions for cardiovascular diseases, with its Barostim product approved for heart failure patients.
CVRx Appoints John Landry as Chief Financial Officer
CVRx, Inc. has announced the appointment of John Landry as its new Chief Financial Officer, succeeding Jared Oasheim. Landry, who will join the company on October 12, 2026, brings over two decades of financial leadership experience in the medical device industry, having previously served as CFO for Nyxoah SA and Vapotherm, Inc. His expertise is expected to help CVRx scale its Barostim therapy and manage expenses effectively.
CVRx, Inc. Appoints John Landry as Chief Financial Officer, Effective October 12, 2026
CVRx, Inc. has announced the appointment of John Landry as its new Chief Financial Officer, effective October 12, 2026. Landry will succeed Jared Oasheim, who will remain with the company for a transition period. Mr. Landry brings over two decades of financial leadership experience in the medical device industry, having previously served as CFO of Nyxoah SA and Senior Vice President and CFO at Vapotherm, Inc., where he led its IPO.
CVRx Faces Fresh Pressure as Activist Pushes a Sale
CVRx, a medical device company, is facing pressure from an activist investor pushing for a sale, amidst modest revenue growth and continued cash burn. The company's future hinges on the success of its BENEFIT-HF clinical trial, broader payer coverage, and strategic initiatives, despite high gross margins on its Barostim product. While the stock trades at a discount, investors are weighing the potential for M&A or clinical success against ongoing profitability and execution risks.
After leading a medical-device company's stock-market debut, John Landry will join CVRx.
CVRx (NASDAQ: CVRX) has announced the appointment of John Landry as its new Chief Financial Officer, succeeding Jared Oasheim. Landry, an experienced medtech finance executive, will join on October 12, 2026, and officially assume the CFO role after the company files its Q3 2026 Form 10-Q. He previously led Nyxoah SA as CFO and oversaw Vapotherm's IPO and financial infrastructure development.
CVRx Appoints John Landry as Chief Financial Officer
CVRx, Inc. has announced the appointment of John Landry as its new Chief Financial Officer, effective after the company files its Q3 2026 Form 10-Q. Landry brings over two decades of financial leadership experience in the medical device industry, having previously served as CFO at Nyxoah SA and Senior Vice President and CFO at Vapotherm, Inc. He will succeed Jared Oasheim, who will remain with the company for a transition period.
Florida Medical Clinic Orlando Health debuts Barostim device in collaboration with CVRx
CVRx has partnered with Florida Medical Clinic Orlando Health to introduce the Barostim implant, an innovative device therapy for heart failure patients. This collaboration marks the first such implant at the clinic, expanding treatment options in the region. CVRx continues to broaden its medical collaborations nationwide, demonstrating its commitment to advancing cardiovascular care.
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against CVRx, Inc. (CVRX) following a significant drop in its stock price. This investigation stems from CVRx's disclosure of a U.S. Department of Justice civil investigative demand concerning alleged false claims, kickbacks, and improper marketing practices, along with a downward revision of its full-year revenue guidance. The firm encourages investors to inquire about the securities investigation.
Jorey Chernett Pushes for Sale at CVRx with 5.5% Stake
Jorey Chernett has disclosed a 5.5% stake in CVRx, Inc. and is actively pushing for the company to initiate a sale process. He sent a letter to the board on August 24, 2026, urging them to retain an independent financial advisor and conduct a full review of strategic options, with a sale as the primary goal. Chernett, a private investor, aims to unlock value in what he views as an undervalued situation.
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX)
CVRx (CVRX) has entered oversold territory after a 31.7% drop in the past four weeks, indicated by its Relative Strength Index (RSI) of 29.38. This technical signal, combined with a 0.9% increase in consensus EPS estimates from analysts over the last 30 days and a Zacks Rank #2 (Buy), suggests a potential rebound. Investors might find this an opportune moment to consider the stock due to the exhaustion of selling pressure and improving fundamental outlook.
CVRx Responds to Letter from Pointillist Family Office
CVRx, Inc. issued a statement in response to a public letter from Pointillist Family Office, affirming its commitment to shareholder interests. The company acknowledges that its Barostim therapy is highly differentiated and that its current valuation does not fully reflect its potential. CVRx expressed confidence in its business fundamentals and strategies to drive Barostim growth while managing expenses, and remains open to constructive engagement with shareholders.
CVRx has an activist investor urging it to get acquired
An activist investor, Pointillist Family Office founder Jorey Chernett, is pressuring CVRx to sell the company to a larger strategic acquirer. Chernett, who owns 5.5% of CVRx, believes that a larger medical device company could better capitalize on the Barostim system's value due to established sales organizations, payer relationships, and financial resources. This push comes after a disappointing second-quarter report and a DOJ civil investigation, causing CVRX shares to drop, although they recently gained 18% following Chernett's call for a sale.
3 Penny Stocks With At Least $70M Market Cap
This article identifies three penny stocks—AlTi Global (ALTI), CVRx (CVRX), and OPKO Health (OPK)—that possess a market capitalization of at least $70 million and strong financial health despite varying profitability statuses. It highlights their current financial positions, recent developments, and future outlooks, emphasizing the importance of underlying financials for growth potential in "penny stocks."
CVRx Responds to Letter from Pointillist Family Office
CVRx, Inc. has issued a statement in response to a letter from Pointillist Family Office, affirming its commitment to shareholder value. The company agrees with Pointillist that its Barostim therapy is highly differentiated and that CVRx's current valuation does not fully reflect its potential. The Board is confident in its business fundamentals and strategies for growth while managing expenses, remaining open to constructive engagement with all shareholders.
New CVRx (NASDAQ: CVRX) investor urges board to prioritize a sale
Private investor Jorey Chernett has acquired a 5.5% stake in CVRx, Inc. (CVRX) for nearly $8 million, stating the shares are undervalued. Chernett has sent a letter to CVRx's Board of Directors, urging them to hire an independent financial advisor and explore strategic alternatives, with a company sale as the primary objective. He plans to remain an active investor and may adjust his holdings or engage in further discussions regarding the company's future.
Law firm investigates CVRx for possible securit...
Block & Leviton is investigating CVRx, Inc. for potential securities law violations after the company cut its full-year revenue forecast and disclosed issues like high sales-force turnover, negative implant growth, and reimbursement problems. CVRx also revealed a Department of Justice civil investigative demand regarding its sales and marketing practices. The investigation aims to determine if CVRx or its executives misled investors.
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
CVRx, Inc. announced that Devoted Health, a major Medicare Advantage provider, has issued a coverage policy for its Barostim therapy, effective July 17, 2026. This policy expands access for patients meeting FDA-approved indications and those in the BENEFIT-HF trial, representing a significant step towards broader insurance coverage for the heart failure treatment. The new coverage, combined with Humana's policy, covers approximately 21% of Medicare Advantage enrollment, following other positive reimbursement developments earlier in 2026.
Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
Jorey Chernett, who beneficially owns over 5.5% of CVRx, Inc. shares, has urged the company's Board of Directors to immediately begin a formal process to sell CVRx to a strategic acquirer. Chernett believes that CVRx's Barostim product would be highly valuable to a large medical device company, leading to immediate shareholder value superior to a standalone strategy. He emphasized the urgency of a sale while the company still has cash, market momentum, and strategic scarcity.
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against CVRx, Inc. (CVRX) following the company's disclosure of a Department of Justice investigation into its sales and marketing practices, including alleged false claims to government health insurance programs and kickbacks. CVRx also lowered its full-year revenue guidance, citing issues with hiring and sales productivity. Shareholders are encouraged to contact the firm to learn more about the investigation.
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against CVRx, Inc. (CVRX) following a significant drop in its stock price. The investigation stems from CVRx's disclosure of a Civil Investigative Demand from the U.S. Department of Justice concerning alleged false claims, improper marketing, and kickbacks related to government health insurance programs. The company also lowered its full-year revenue guidance due to issues with hiring and sales productivity.
Investigation launched into CVRx over DOJ probe, sales issues, and sudden CRO firing
Hagens Berman has initiated an investigation into CVRx Inc. following a U.S. Department of Justice Civil Investigative Demand regarding potential false claims and kickbacks tied to its Barostim heart failure device. This comes after CVRx drastically cut its 2026 revenue guidance due to sales force problems and reduced Medicare Advantage approvals, leading to a 59% stock drop and the abrupt termination of its Chief Revenue Officer. The investigation will examine these events for possible internal issues and investor misinformation.
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
Hagens Berman, a national securities law firm, is investigating CVRx Inc. (CVRX) for potential securities fraud after a 59% stock drop. The investigation follows disclosures of a U.S. Department of Justice Civil Investigative Demand, significant cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company's Chief Revenue Officer. Investors with substantial losses are encouraged to contact the firm.
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
CVRx (CVRX) stock has recently experienced a bearish trend, losing 16.7% over the past four weeks, but a hammer chart pattern suggests a potential trend reversal. This technical indicator, combined with strong upward revisions in earnings estimates by Wall Street analysts and a Zacks Rank #2 (Buy), indicates that the stock might be finding support and could see price appreciation. The article explains how a hammer chart pattern works and highlights the fundamental factors supporting a bullish outlook for CVRX.
Law firm investigates CVRx for possible securities violations after revenue guidance cut and DOJ probe.
Block & Leviton is investigating CVRx, Inc. for potential securities law violations. This comes after CVRx lowered its full-year revenue guidance due to sales-force issues and reimbursement problems, and also disclosed a Department of Justice civil investigative demand regarding its sales and marketing practices. The investigation seeks to determine if investors were adequately informed about these issues earlier.
Cantor Fitzgerald Maintains CVRx Inc(CVRX.US) With Buy Rating, Cuts Target Price to $5
Cantor Fitzgerald has reiterated its "Buy" rating for CVRx Inc (CVRX.US) but has reduced the target price for the stock to $5. This decision indicates a continued positive outlook on the company's prospects despite a lower price expectation.
Cantor cuts CVRx stock price target on sales execution challenges By Investing.com
Cantor Fitzgerald lowered its price target for CVRx Inc (NASDAQ:CVRX) to $5.00 from $13.00, citing near-term sales execution and reimbursement pressures, despite maintaining an "Overweight" rating. The company's Q2 2026 results reflected challenges in specific regions with new leadership and hiring pressures, leading to a lowered 2026 guidance. Despite these headwinds, CVRx maintains an 87% gross profit margin and strong liquidity.
Cantor Fitzgerald Issues Pessimistic Forecast for CVRx (NASDAQ:CVRX) Stock Price
Cantor Fitzgerald has cut its price target for CVRx (NASDAQ:CVRX) from $13 to $5, although it maintains an "overweight" rating, suggesting a significant upside. This reduction aligns with a general weakening of analyst sentiment, leading to a consensus "Hold" rating and an average price target of $5.30 for CVRx. The company recently reported a quarterly loss worse than estimates and a negative net margin, impacting its stock performance.
Cvrx COO Brent Binkowski sells $3,338 in company stock
CVRx COO Brent Binkowski sold 1,309 shares of the company's stock for a total of $3,338 in a sell-to-cover transaction to meet tax obligations. Following this sale, Binkowski directly holds 30,291 shares. The company recently reported a 16% increase in Q2 revenue but lowered its full-year outlook due to sales force and reimbursement challenges, leading Piper Sandler to downgrade its stock rating.
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
Hagens Berman, a national shareholder rights litigation firm, has initiated an investigation into CVRx Inc. (CVRX) for potential federal securities law violations. This investigation follows a 59% stock drop after the company disclosed a U.S. Department of Justice Civil Investigative Demand, severe revenue guidance cuts, sales force disruption, and the unexpected termination of its Chief Revenue Officer. The firm is encouraging CVRx investors who have experienced substantial losses to contact them to evaluate their legal rights and recovery options, and is also seeking whistleblowers with non-public information.
CVRx, Inc. (CVRX) investor Jorey Chernett discloses 5.5% beneficial stake
Investor Jorey Chernett has disclosed a 5.5% beneficial ownership stake in CVRx, Inc. (CVRX), holding 1,461,750 shares of common stock. This ownership grants Chernett sole voting and dispositive power over these shares, based on CVRx's 26,641,597 outstanding shares as of July 30, 2026. The disclosure was made via a SCHEDULE 13G filing, indicating a passive investment.
Insider Purchase: CHIEF OPERATING OFFICER of $CVRX Buys 26,223 Shares
The Chief Operating Officer of CVRX (CVRX) recently purchased 26,223 shares of the company's stock. This insider transaction signals confidence in the company's future prospects from a key executive.
Cvrx COO Brent Binkowski sells $3,338 in company stock
Brent Binkowski, COO of CVRx, Inc., sold 1,309 shares of company stock for $3,338 in a sell-to-cover transaction to satisfy tax obligations. This sale comes as CVRx reported increased Q2 revenue but lowered its full-year outlook due to sales force and reimbursement challenges, leading Piper Sandler to downgrade the stock.
Cvrx COO Brent Binkowski buys $76,432 in company stock
CVRx COO Brent Binkowski purchased 26,223 shares of the company's common stock for $76,432 on August 13, 2026, increasing his direct ownership to 56,514 shares. This insider purchase occurs while the stock is near its 52-week low, with InvestingPro suggesting it is undervalued. The company recently reported Q2 revenue growth but lowered its full-year outlook due to sales force issues and reimbursement challenges, leading to a downgrade by Piper Sandler.
CVRx (NASDAQ:CVRX) COO Brent Binkowski Buys 26,223 Shares of Stock
CVRx COO Brent Binkowski recently purchased 26,223 shares of CVRx stock for $2.91 per share, increasing his total holdings to 56,514 shares. This purchase followed a sale of 1,309 shares the previous day. Despite the insider buying and a 7.7% stock increase, CVRx continues to face profitability challenges and has received several analyst downgrades, resulting in a consensus "Hold" rating with an average price target of $6.90.
Insider Purchase: CHIEF OPERATING OFFICER of $CVRX Buys 26,223 Shares
Brent Binkowski, the Chief Operating Officer of CVRX, purchased 26,223 shares of the company stock for an estimated $76,432, increasing his holdings by 86.6%. This transaction was part of 9 insider trades in the past six months, with 3 purchases and 6 sales. The article also details recent hedge fund activity in CVRX, showing both increased and decreased institutional investor positions.
CVRx (CVRX) COO Brent Binkowski purchases 26,223 shares in open-market buy
Brent Binkowski, Chief Operating Officer of CVRx, Inc. (CVRX), purchased 26,223 shares of the company's common stock on August 13, 2026. The open-market transactions occurred at a weighted average price of $2.9147 per share, with individual trade prices ranging from $2.87 to $2.96. Following these purchases, Binkowski directly holds 56,514 shares of CVRx common stock.
